MacroGenics, Inc. MGNX
Analyst Ratings
- Consensus
- Moderate Buy — 2 Buy · 1 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $6.33 (+69.3% upside)
Key Stats
- Today's Range
- $3.72 – $3.86
- 50-Day Range
- $3.36 – $4.63
- 52-Week Range
- $1.29 – $5.08
- Volume
- 605K shs
- Average Volume
- 467K shs
- Market Cap
- $238.24 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 5.56
- Price / Sales
- 1.55
Short Interest
- Short Interest
- 7.54%
- Days to Cover
- 33.12
Financials (TTM)
- Revenue
- $153.62 million
- Net Income
- $-14,592,000
- Net Margin
- -9.50%
- Return on Equity
- -34.04%
- Debt-to-Equity
- —
About MacroGenics, Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Related Stocks
Compare head-to-head: MGNX vs LLY·MGNX vs JNJ·MGNX vs ABBV·MGNX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.